The U.S. Health Resources and Services Administration (HRSA) today turned the screws tighter on Boehringer Ingelheim (BI) over its “continued failure to provide the 340B price to covered entities utilizing contract pharmacies.”
HRSA told BI in a March 29 letter that it was referring the issue to the U.S. Health and Human Services Department (HHS) Office of Inspector General (OIG) for possible imposition of civil monetary penalties (CMPs) “given BI’s continued refusal to comply” with a 340B program violation letter that HRSA sent it on Oct. 4, 2021.
The U.S. Health Resources and Services Administration (HRSA) today turned the screws tighter on Boehringer Ingelheim (BI) over its “continued failure to provide the 340B price to covered entities utilizing contract pharmacies.”
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
